NCT04987320

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(a)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of Olpasiran in Chinese participants with elevated serum lipoprotein(a) (Lp\[a\]).

Conditions

• Elevated Serum Lipoprotein(a)

Interventions

Type	Name	Description
DRUG	Olpasiran	Subcutaneous injection

Timeline

• Start date: 2021-07-28
• Primary completion: 2021-11-12
• Completion: 2022-03-18
• First posted: 2021-08-03
• Last updated: 2025-02-10
• Results posted: 2025-02-10

Locations

1 site across 1 country: Hong Kong

Regulatory

• FDA-regulated drug study